- Home
- SES vs XOMA Comparison
SES vs XOMA Comparison
Compare SES & XOMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SES
- XOMA
- Stock Information
- Founded
- SES 2012
- XOMA 1981
- Country
- SES United States
- XOMA United States
- Employees
- SES N/A
- XOMA N/A
- Industry
- SES Auto Parts:O.E.M.
- XOMA Biotechnology: Pharmaceutical Preparations
- Sector
- SES Consumer Discretionary
- XOMA Health Care
- Exchange
- SES Nasdaq
- XOMA Nasdaq
- Market Cap
- SES 384.0M
- XOMA 330.2M
- IPO Year
- SES N/A
- XOMA N/A
- Fundamental
- Price
- SES $1.12
- XOMA $32.47
- Analyst Decision
- SES Hold
- XOMA Strong Buy
- Analyst Count
- SES 3
- XOMA 2
- Target Price
- SES $1.50
- XOMA $69.50
- AVG Volume (30 Days)
- SES 5.6M
- XOMA 57.0K
- Earning Date
- SES 08-04-2025
- XOMA 08-13-2025
- Dividend Yield
- SES N/A
- XOMA N/A
- EPS Growth
- SES N/A
- XOMA N/A
- EPS
- SES N/A
- XOMA N/A
- Revenue
- SES $11,360,000.00
- XOMA $44,952,000.00
- Revenue This Year
- SES $883.92
- XOMA $82.30
- Revenue Next Year
- SES $159.98
- XOMA $12.59
- P/E Ratio
- SES N/A
- XOMA N/A
- Revenue Growth
- SES N/A
- XOMA 194.98
- 52 Week Low
- SES $0.20
- XOMA $18.35
- 52 Week High
- SES $2.53
- XOMA $35.23
- Technical
- Relative Strength Index (RSI)
- SES 51.03
- XOMA 61.79
- Support Level
- SES $1.09
- XOMA $32.60
- Resistance Level
- SES $1.22
- XOMA $34.60
- Average True Range (ATR)
- SES 0.07
- XOMA 1.82
- MACD
- SES -0.00
- XOMA 0.09
- Stochastic Oscillator
- SES 55.32
- XOMA 66.75
About SES SES AI Corporation
SES AI Corp is a developer and manufacturer of high-performance, AI-enhanced Lithium-Metal (Li-Metal) and Lithium-ion (Li-ion) rechargeable battery technologies for electric vehicles (EVs), Urban Air Mobility (UAM), drones, robotics, Battery Energy Storage Systems (BESS) and other applications. It includes Software and Hardware products that are EV, UAM, Drone, Molecular Universe, and Avatar.
About XOMA XOMA Corporation
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Geographically, the company operates in Switzerland, United States, Asia Pacific, Europe and Others.